Compare Bristol-Myers Squibb Co (BMY) vs Fabrinet (FN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Fabrinet — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Fabrinet trades at $580 (market cap $18.84B). The key difference: Bristol-Myers Squibb Co is far larger — about 6.9× Fabrinet's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| BMY | FN | |
|---|---|---|
Market Cap | $129.94B | $18.84B |
Sector | Health | Technology |
52-Week High | $65.89 | $746.47 |
52-Week Low | $42.60 | $277.04 |
Enterprise Value | $163.92B | $17.90B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Fabrinet (FN) trades at $571.78, up 8.48% in the last session, showing strong momentum despite a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Analyst consensus remains strongly bullish with 75% buy ratings, supported by Fabrinet's strategic positioning in AI optical manufacturing and robust revenue growth projections.
The outlook remains positive given Fabrinet's critical role in AI infrastructure and strong financial performance, though premium valuation metrics and technical overbought conditions present near-term risks. Continued execution on capacity expansion and AI-driven demand should support long-term growth, but investors should monitor supply chain constraints and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →
